136 related articles for article (PubMed ID: 20212356)
1. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation.
Schwarz RE; Awasthi N; Konduri S; Caldwell L; Cafasso D; Schwarz MA
Cancer Biol Ther; 2010 Apr; 9(8):632-9. PubMed ID: 20212356
[TBL] [Abstract][Full Text] [Related]
2. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
3. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
5. Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
Cancer Biol Ther; 2010 Jul; 10(1):99-107. PubMed ID: 20495354
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
[TBL] [Abstract][Full Text] [Related]
7. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
Awasthi N; Schwarz MA; Schwarz RE
Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
9. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
[TBL] [Abstract][Full Text] [Related]
10. An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
Schwarz RE; Konduri S; Awasthi N; Cafasso D; Schwarz MA
Surgery; 2009 Aug; 146(2):241-9. PubMed ID: 19628080
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model.
Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI
Exp Oncol; 2007 Dec; 29(4):267-71. PubMed ID: 18199981
[TBL] [Abstract][Full Text] [Related]
12. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.
Awasthi N; Schwarz MA; Verma V; Cappiello C; Schwarz RE
Lab Invest; 2009 Jan; 89(1):38-46. PubMed ID: 19002109
[TBL] [Abstract][Full Text] [Related]
13. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Berger AC; Alexander HR; Tang G; Wu PS; Hewitt SM; Turner E; Kruger E; Figg WD; Grove A; Kohn E; Stern D; Libutti SK
Microvasc Res; 2000 Jul; 60(1):70-80. PubMed ID: 10873516
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model.
Guimaraes AR; Rakhlin E; Weissleder R; Thayer SP
Pancreas; 2008 Nov; 37(4):440-4. PubMed ID: 18953259
[TBL] [Abstract][Full Text] [Related]
15. Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin.
Schwarz MA; Zheng H; Liu J; Corbett S; Schwarz RE
Exp Cell Res; 2005 Dec; 311(2):229-39. PubMed ID: 16248999
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Endothelial Monocyte-Activating Polypeptide-II Increases Blood-Tumor Barrier Permeability by Activating the RhoA/ROCK/PI3K Signaling Pathway.
Li Z; Liu XB; Liu YH; Xue YX; Liu J; Teng H; Xi Z; Yao YL
J Mol Neurosci; 2016 Jun; 59(2):193-202. PubMed ID: 26521255
[TBL] [Abstract][Full Text] [Related]
18. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer.
Guha S; Eibl G; Kisfalvi K; Fan RS; Burdick M; Reber H; Hines OJ; Strieter R; Rozengurt E
Cancer Res; 2005 Apr; 65(7):2738-45. PubMed ID: 15805273
[TBL] [Abstract][Full Text] [Related]
19. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
20. Low-dose endothelial monocyte-activating polypeptide-II increases permeability of blood-tumor barrier via a PKC-ζ/PP2A-dependent signaling mechanism.
Li Z; Liu YH; Liu XB; Xue YX; Wang P; Liu LB
Exp Cell Res; 2015 Feb; 331(2):257-66. PubMed ID: 25592443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]